Showing 5961-5970 of 10623 results for "".
- Elraglusib Plus Chemotherapy Shows Survival Gain In Pancreatic Cancer Trialhttps://reachmd.com/news/elraglusib-plus-chemotherapy-shows-survival-gain-in-pancreatic-cancer-trial/2486612/Investigators reported that adding elraglusib to standard chemotherapy was associated with longer overall survival than chemotherapy alone in metastatic pancreatic cancer. The comparis
- Female Authorship Rises in Facial Plastic Surgery Literature, But Gaps Remainhttps://reachmd.com/news/female-authorship-rises-in-facial-plastic-surgery-literature-but-gaps-remain/2486534/A cross-sectional bibliometric analysis published in Facial Plastic Surgery & Aesthetic Medicine examined trends in female authorship across facial plastic surgery literature from 2007 to 2022. The study evaluated 6,921 original research articles from 3 journals, assessing authorship
- Female Authorship Rises in Facial Plastic Surgery Literature, But Gaps Remainhttps://reachmd.com/news/female-authorship-rises-in-facial-plastic-surgery-literature-but-gaps-remain/2486533/A cross-sectional bibliometric analysis published in Facial Plastic Surgery & Aesthetic Medicine examined trends in female authorship across facial plastic surgery literature from 2007 to 2022. The study evaluated 6,921 original research articles from 3 journals, assessing authorship
- Lebrikizumab Shows Durable Efficacy Through 4 Years in Atopic Dermatitishttps://reachmd.com/news/lebrikizumab-shows-durable-efficacy-through-4-years-in-atopic-dermatitis/2486468/Long-term data from the Phase 3b ADlong study show that lebrikizumab provides sustained skin clearance and itch relief for up to four years in patients with moderate-to-severe atopic dermatitis (AD), according to findings presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting.
- AAD 2026: Survey Highlights Facial Concerns Among GLP-1 Weight Loss Patientshttps://reachmd.com/news/aad-2026-survey-highlights-facial-concerns-among-glp-1-weight-loss-patients/2486397/A large survey presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado, highlights evolving aesthetic concerns among patients receiving glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss. The analysis, based on responses from 406 US healthcare
- Survey Highlights Misinformation’s Growing Impact on Public Trust and Health Perceptionhttps://reachmd.com/news/survey-highlights-misinformations-growing-impact-on-public-trust-and-health-perception/2486387/A new national survey from The Harris Poll paints a complex and increasingly consequential picture of how Americans engage with health and science inf
- Perceived Social Support, Resilience, Mindfulness, and Learning Engagementhttps://reachmd.com/news/perceived-social-support-resilience-mindfulness-learning-engagement/2486377/Among Chinese vocational students, investigators report that higher perceived social support was associated with higher learning engagement, with emotional resilience and mindfulness modeled as m
- New Findings on Isolate-Level UTI Resistancehttps://reachmd.com/news/isolate-level-uti-resistance/2486352/Investigators from a single Romanian clinical center report isolate-level UTI resistance (2019–2024) using urine culture results generated between 2019 a
- Population-Level HPV Vaccine Impact Among Girls with HIV in South Africahttps://reachmd.com/news/news-report-population-level-hpv-vaccine-impact-among-girls-with-hiv-in-south-africa/2486328/A report on research published in The Lancet Global Health described a population-level HPV vaccine evaluation in South Africa, including reductions in vaccine-type HPV infections after imp
- National Survey Findings on Obesity Prevalence in High School Studentshttps://reachmd.com/news/survey-obesity-prevalence-high-school/2486310/New Youth Risk Behavior Survey (YRBS) findings show that obesity prevalence among US high school students (grades 9–12) rose